Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis
Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis have?
Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis has 83 citations in the OpenAlex counts ScholarIQ stores.
When was Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis published?
Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis has 2021 year in the ScholarIQ index.
What is the open-access status of Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis?
Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis has hybrid oa status in the ScholarIQ index.
What is the DOI of Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis?
The DOI for Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis is on the source record.
What is the PMID of Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis?
The PMID for Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis is on the source record.
What is the OpenAlex record for Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis?
The OpenAlex for Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis is on the source record.